Cytokinetics Inc Stock Price, News & Analysis

Cytokinetics has commenced enrollment in Cohort 3 of its Phase 2 clinical trial, REDWOOD-HCM, evaluating CK-274 for hypertrophic cardiomyopathy (HCM) patients on disopyramide. This cohort aims to assess safety, tolerability, and pharmacokinetics of CK-274. Preliminary findings from earlier cohorts indicated significant reductions in left ventricular outflow tract gradients without major safety concerns. Results from Cohorts 1 and 2 are anticipated mid-2021. CK-274 has been developed to target hypercontractility in HCM, with no FDA-approved treatments currently available.

Cytokinetics granted stock options to purchase 69,800 shares to six new employees as an inducement for employment, effective April 30, 2021. The options have an exercise price of $25.44 per share, equal to the closing stock price on that date. Vesting occurs over four years, with the first quarter vesting after one year and the remainder monthly thereafter. This grant was sanctioned by the Compensation and Talent Committee and complies with Nasdaq rules. The company focuses on muscle-related drug development and prepares for regulatory action on its cardiac muscle activator, omecamtiv mecarbil.

Cytokinetics (Nasdaq: CYTK) will report its first quarter results on May 6, 2021, at 4:00 PM Eastern Time, followed by a conference call at 4:30 PM. This call will discuss operational and financial results and the company's future outlook. Investors can access the call via the company's website or by dialing designated numbers. An archived replay will be available until May 20, 2021. Cytokinetics specializes in muscle activators and inhibitors for treating diseases affecting muscle performance, with ongoing clinical trials for its drug candidates.

Cytokinetics (Nasdaq: CYTK) recently presented data on CK-274, its next-in-class cardiac myosin inhibitor, at the American Chemical Society Spring 2021 Virtual Meeting. The presentation highlighted CK-274's chemical structure, exposure-response relationship, and pharmacokinetics, particularly its projected human half-life of 2.8 days. Preclinical results indicated CK-274 effectively reduced cardiac contractility and demonstrated a favorable pharmacodynamic window. The ongoing REDWOOD-HCM Phase 2 trial is set to evaluate CK-274's efficacy and safety in patients with obstructive hypertrophic cardiomyopathy (HCM).

Cytokinetics announced that Robert I. Blum, President and CEO, will participate in a virtual fireside chat at the 20th Annual Needham Virtual Healthcare Conference on April 12, 2021, at 3:00 PM ET. Interested parties can access the live webcast on the Cytokinetics website, with a replay archived for 90 days post-event. Cytokinetics focuses on developing muscle activators and inhibitors for diseases affecting muscle performance, currently advancing candidates like omecamtiv mecarbil for heart failure and CK-274 for hypertrophic cardiomyopathy.

Cytokinetics, incorporated (Nasdaq: CYTK), will present data on CK-274, a cardiac myosin inhibitor aimed at treating hypertrophic cardiomyopathies (HCM), at the American Chemical Society Spring 2021 Virtual Meeting from April 5 to April 30, 2021. The presentation titled 'Discovery of CK-274' is scheduled for April 9, 2021, featuring Dr. Grace Chuang. The company is advancing several clinical trials, including the REDWOOD-HCM Phase 2 study for CK-274 and the METEORIC-HF Phase 3 study for omecamtiv mecarbil, after positive results from previous trials.

Cytokinetics announced the granting of stock options for 163,700 shares to three new employees as an inducement for their employment. This includes 150,000 shares to the new chief commercial officer, Andrew Callos. The options were granted at an exercise price of $23.26, the closing price on March 31, 2021. Vesting will occur over four years, starting with 1/4 of the shares after one year. The options are part of the company's 2004 Equity Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4).

Cytokinetics announced a secondary analysis of the GALACTIC-HF trial, focusing on omecamtiv mecarbil's effects on heart failure patients with varying baseline ejection fractions. This data will be presented on May 17, 2021, at the ACC Annual Scientific Session. The company is preparing for regulatory discussions regarding omecamtiv mecarbil, following positive results from the Phase 3 trial. Cytokinetics is also progressing in other trials, including METEORIC-HF for omecamtiv mecarbil and REDWOOD-HCM for CK-274, a cardiac myosin inhibitor.

Cytokinetics, Incorporated (Nasdaq: CYTK) announced that CEO Robert I. Blum will present at the virtual H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021, and at the Barclays Global Healthcare Conference on March 11, 2021, at 9:45 AM ET. Interested parties can access the pre-recorded presentation and live webcast via Cytokinetics' website. The company focuses on developing muscle activators and inhibitors for diseases impairing muscle performance. Key products include omecamtiv mecarbil and CK-274, aimed at treating heart failure and hypertrophic cardiomyopathy, respectively.